Our Commitment to Safety Communication

The Prescribing Information is the primary source of information on the known and potential risks of ocrelizumab for relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).

Data is drawn from the experience of patients who have started on ocrelizumab globally (as of March 2023):

• >300,000 patients (>750,000 patient-years), including >9,800 patients from clinical trials and open-label extension¹

The following ocrelizumab global safety updates are available. Click below to learn more:

Indication:

Ocrelizumab is indicated for the treatment of: 

• Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
• Primary progressive MS, in adults
  

Report an Adverse Event:
Phone: (888) 835-2555
Hours: 24 hrs/day, 7 days/week

Medical Communications:
Submit a question online
Phone: (800) 821-8590
Hours: Monday - Friday, 5am - 5pm PT

Contact an MSL:
Request follow-up with a Genentech medical science liaison (MSL)